Agomelatine as monotherapy for major depression: an outpatient, open-label study

BACKGROUND: Agomelatine is a novel antidepressant agonist to MT1 and MT2 subtypes of melatoninergic receptors (MT1 and MT2) and antagonist to 5-HT(2C) subtype of serotonergic (5-HT(2C)) receptors, which has shown antidepressant efficacy in short-term and long-term trials as well as in clinical pract...

Descripción completa

Detalles Bibliográficos
Autores principales: Pecenak, Jan, Novotny, Vladimir
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2013
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3808155/
https://www.ncbi.nlm.nih.gov/pubmed/24174876
http://dx.doi.org/10.2147/NDT.S49062

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3808155/
https://www.ncbi.nlm.nih.gov/pubmed/24174876
http://dx.doi.org/10.2147/NDT.S49062

Ejemplares similares